



### TABLE OF CONTENTS

---

●	<b>Description</b>	<b>p.1</b>
●	<b>Impact Factor</b>	<b>p.1</b>
●	<b>Editorial Board</b>	<b>p.1</b>
●	<b>Guide for Authors</b>	<b>p.3</b>



ISSN: 1734-1140

### DESCRIPTION

---

**Pharmacological Reports** publishes articles concerning all aspects of **pharmacology, dealing with the action of drugs** at a **cellular** and **molecular level**, and papers on the relationship between molecular structure and **biological activity** as well as **reports on compounds** with well-defined **chemical structures**.

**Pharmacological Reports** is an open forum to disseminate recent developments in: **pharmacology, behavioural brain research, evidence-based complementary biochemical pharmacology, medicinal chemistry and biochemistry, drug discovery, neuro-psychopharmacology and biological psychiatry, neuroscience and neuropharmacology, cellular and molecular neuroscience, molecular biology, cell biology, toxicology.**

**Studies of plant extracts are not suitable for Pharmacological Reports.**

Original research articles, reviews and short communications are welcomed. The journal guarantees rapid publication of accepted papers that comprises a dedicated fast acceptance and publication track for high profile articles.

**Pharmacological Reports** is the official journal of the [Institute of Pharmacology of the Polish Academy of Sciences](#)

Please see our [Guide for Authors](#) for information on article submission.

#### **Benefits to authors**

We also provide many author benefits, such as free PDFs, a special discounts on Elsevier publications and much more. Please click here for more information on our [author services](#).

### IMPACT FACTOR

---

2016: 2.587 © Thomson Reuters Journal Citation Reports 2017

### EDITORIAL BOARD

---

#### **Editor-in-Chief**

**Małgorzata Filip**, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland

#### **Deputy Editor**

**Grażyna Skuza**, Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland

### **Managing Editor**

**Beata Kreiner**, Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland

### **Field Editors**

**Andrzej Bojarski**, Inst. of Pharmacology, Polish Academy of Sciences, Krakow, Poland

**Danuta Jantas**, Inst. of Pharmacology, Polish Academy of Sciences, Krakow, Poland

**Michał Korostynski**, Inst. of Pharmacology, Polish Academy of Sciences, Krakow, Poland

**Agnieszka Nikiforuk**, Inst. of Pharmacology, Polish Academy of Sciences, Krakow, Poland

**Rafał Olszanecki**, Collegium Medicum Jagiellonian University, Kraków, Poland

**Joanna Pera**, Collegium Medicum Jagiellonian University, Kraków, Poland

**Jacek Wojcikowski**, Inst. of Pharmacology, Polish Academy of Sciences, Krakow, Poland

**Magdalena Zielinska**, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warszawa, Poland

### **Advisory Board**

**Carmen Abate**, Università degli Studi di Bari Aldo Moro, Bari, Italy

**Martine Ammassari-Teule**, Institute of Cell Biology and Neurobiology, Italian National Research Council, Roma, Italy

**Włodzimierz Buczek**, Higher Vocational School in Suwałki, Suwałki, Poland

**Halina Car**, Medical University of Białystok, Białystok, Poland

**John Cryan**, Dept. of Anatomy & Neuroscience, University College Cork, Cork, Ireland

**Kathryn A. Cunningham**, University of Texas Medical Branch, Galveston, Texas, USA

**Stanisław Czuczwar**, Dept. of Pathophysiology, Medical Academy in Lublin, Lublin, Poland

**Władysława Daniel**, Dept. of Pharmacokinetics and Drug Metabolism, Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland

**Agnieszka Dobrzyn**, Nencki Institute of Experimental Biology, Polish Academy of Sciences, Warszawa, Poland

**Marek Drozdziak**, Pomeranian Medical University, Szczecin, Poland

**Jakub Fichna**, Uniwersytet Medyczny w Łodzi, Lodz, Poland

**Fabio Fumagalli**, University of Milan, Milan, Italy

**Kjell Fuxe**, Dept. of Neuroscience, Karolinska Institutet, Stockholm, Sweden

**Maria Trinidad Herrera Exquerro**, Department of Morphological Sciences and Psychobiology, Universidad de Murcia, Murcia, Spain

**Kenneth Jacobson**, National Institutes of Health (NIH), Bethesda, Maryland, USA

**Jacek Kuznicki**, International Institute of Molecular and Cell Biology in Warsaw, Poland

**Władysław Lason**, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland

**Barbara Malinowska**, Dept. of Experimental Physiology and Pathophysiology, Medical University of Białystok, Białystok, Poland

**Eva M. Marco**, Universidad Complutense de Madrid, Madrid, Spain

**Dimitri P. Mikhailidis**, University College London Medical School, London, England, UK

**Christian P. Müller**, Dept. of Psychiatry and Psychotherapy, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

**Irena Nalepa**, Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland

**Andrzej Pilc**, Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland

**Edmund Przegalinski**, Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland

**Barbara Przewłocka**, Dept. of Pharmacology of Pain, Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland

**Patricia Salinas**, University College London (UCL), London, UK

**Barbara Zabłocka**, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warszawa, Poland

**Jolanta Zawilska**, Uniwersytet Medyczny w Łodzi, Lodz, Poland

## GUIDE FOR AUTHORS

---

### INTRODUCTION

#### *Criteria for manuscripts*

The Editorial Board of *Pharmacological Reports* takes under consideration for publication original articles with the understanding that neither the manuscript nor any part of its essential substance, tables or figures have been published previously in print form or electronically and are not under consideration by any other publication or electronic medium. Copies of any closely related manuscripts should be submitted to the Editor along with the manuscript that is to be considered by *Pharmacological Reports*. Each submission packet should include the statement signed by the first author that the work has not been published previously or submitted elsewhere for review and a copyright transfer.

*Pharmacological Reports* publishes papers concerning all aspects of pharmacology, dealing with the drug action at the cellular and molecular level, and papers on relationship between molecular structure and biological activity. Studies of plant extracts are not suitable for *Pharmacological Reports*. We only publish reports on compounds with well-defined chemical structures. The language of all publications is English.

#### *Types of publication*

The journal features publications of the following categories: regular papers, short communications, and review articles.

*Regular papers* should present new experimental studies that constitute a significant contribution to existing knowledge. Theoretical papers that deal with new ideas and concepts based on earlier findings will also be welcome.

*Short communications* should present important new findings in a brief form.

*Review articles* should cover the most important current topics or present interpretative and critical accounts. They should not be simple compilations on subjects of general interest. Review articles are published only by invitation of the Editor-in-Chief. Authors intending to prepare a review should first contact the Editors.

The maximum length of regular papers is 5,000 words, and 9,000 words is the maximum for review articles. The length of short communications should not exceed 3,000 words, four illustrations (figures and tables), and 20 references. The word count includes abstracts, references, tables and figure captions.

An abstract should not exceed 250 words.

### BEFORE YOU BEGIN

#### *Ethics in publishing*

Please see our information pages on [Ethics in publishing](#) and [Ethical guidelines for journal publication](#).

#### *Human and animal rights*

If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with [The Code of Ethics of the World Medical Association](#) (Declaration of Helsinki) for experiments involving humans; [Uniform Requirements for manuscripts submitted to Biomedical journals](#). Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

All animal experiments should comply with the [ARRIVE guidelines](#) and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, [EU Directive 2010/63/EU for animal experiments](#), or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and the authors should clearly indicate in the manuscript that such guidelines have been followed.

#### *Declaration of interest*

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places: 1. A summary declaration of interest statement in the title page file (if double-blind) or the manuscript file (if single-blind). If there are no interests to declare then please state this: 'Declarations of interest:

none'. This summary statement will be ultimately published if the article is accepted. 2. Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the journal's official records. It is important for potential interests to be declared in both places and that the information matches. [More information](#).

### **Submission declaration and verification**

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see '[Multiple, redundant or concurrent publication](#)' section of our ethics policy for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service [CrossCheck](#).

### **Contributors**

Each author is required to declare his or her individual contribution to the article: all authors must have materially participated in the research and/or article preparation, so roles for all authors should be described. The statement that all authors have approved the final article should be true and included in the disclosure.

### **Changes to authorship**

Authors are expected to consider carefully the list and order of authors **before** submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only **before** the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the **corresponding author**: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors **after** the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

### **Copyright**

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see [more information](#) on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. [Permission](#) of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has [preprinted forms](#) for use by authors in these cases.

For open access articles: Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' ([more information](#)). Permitted third party reuse of open access articles is determined by the author's choice of [user license](#).

### **Author rights**

As an author you (or your employer or institution) have certain rights to reuse your work. [More information](#).

#### *Elsevier supports responsible sharing*

Find out how you can [share your research](#) published in Elsevier journals.

### **Role of the funding source**

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

#### *Funding body agreements and policies*

Elsevier has established a number of agreements with funding bodies which allow authors to comply with their funder's open access policies. Some funding bodies will reimburse the author for the Open Access Publication Fee. Details of [existing agreements](#) are available online.

#### *Green open access*

Authors can share their research in a variety of different ways and Elsevier has a number of green open access options available. We recommend authors see our [green open access page](#) for further information. Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository after an embargo period. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications. Embargo period: For subscription articles, an appropriate amount of time is needed for journals to deliver value to subscribing customers before an article becomes freely available to the public. This is the embargo period and it begins from the date the article is formally published online in its final and fully citable form. [Find out more](#).

This journal has an embargo period of 12 months.

### **Language (usage and editing services)**

Please write your text in good English (only American usage is accepted). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's WebShop <http://webshop.elsevier.com/languageediting/> or visit our customer support site <http://support.elsevier.com> for more information. Authors who are not native English speakers are requested to attach a certificate at the time of submission confirming that professional language editing has been performed.

### **Submission**

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

#### *Submit your article*

Please submit your article via <https://www.evis.com/profile/api/navigate/PHAREP>.

#### *Referees*

Please submit the names and institutional e-mail addresses of several potential referees. For more details, visit our [Support site](#). Note that the editor retains the sole right to decide whether or not the suggested reviewers are used.

### **Review process**

Manuscripts are evaluated on the basis that they present new insights to the investigated topic, are likely to contribute to a research progress. It is understood that all authors listed on a manuscript have agreed to its submission. The signature of the corresponding author on the letter of submission signifies that these conditions have been fulfilled. Received manuscripts are first examined by the Editors of *Pharmacological Reports*. Manuscripts with insufficient priority for publication are rejected promptly. Incomplete packages or manuscripts not prepared in the advised style will be sent back to authors without scientific review. The authors are notified with the reference number upon manuscript registration at the Editorial Office. The registered manuscripts are sent to independent experts for scientific evaluation. We highly encourage authors to include a list of four potential reviewers for their manuscript, with complete contact information, but we reserve the right of final selection. Submitted papers are accepted for publication after a positive opinion of the independent reviewers.

## Permissions

Materials taken from other sources must be accompanied by a written statement from both author and publisher giving permission to *Pharmacological Reports* for reproduction. Obtain permission in writing from at least one author of papers still in press, unpublished data, and personal communications.

## Disclaimer

Every effort is made by the Editor-in-Chief and the Editorial Board of *Pharmacological Reports* to see that no inaccurate or misleading data, opinion or statement appear in *Pharmacological Reports*. However, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor, sponsor or advertiser concerned. Accordingly, the Editor-in-Chief and the Editorial Board accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement. Every effort is made to ensure that drug doses and other quantities are presented accurately. Nevertheless, readers are advised that methods and techniques involving drug usage and other treatments described in *Pharmacological Reports*, should only be followed in conjunction with the drug or treatment manufacturer's own published literature in the readers own country.

## PREPARATION

### Peer review

This journal operates a double blind review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. [More information on types of peer review.](#)

### Use of word processing software

It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the [Guide to Publishing with Elsevier](#)). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

### Article structure

#### Subdivision

Divide your article into clearly defined and unnumbered sections.. Any subsection may be given a brief heading. Each heading should appear on its own separate line.

#### Introduction

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

#### Material and methods

Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described.

Authors should adhere very carefully to the ethical standards for animal experimentation. Appropriate guidelines for the acquisition and care of animals can be found in the NIH Guide for the Care and Use of Laboratory Animals (National Institutes of Health Publications No. 8023, revised 1978).

#### Results

Results should be clear and concise.

### *Discussion*

This should explore the significance of the results of the work, not repeat them. In short communications, the Results and Discussion sections may be combined. Avoid extensive citations and discussion of published literature.

### **Essential title page information**

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. **Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.**
- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

### **Acknowledgements**

Collate acknowledgements in a separate section and include it on the title page only. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

### **Abstract**

A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

The abstract must be structured into separate sections: Background outlining the context and purpose of the study; Methods containing a short description of methodologies used; Results reporting the main findings; and Conclusions including a brief summary and potential implications. The abstract should be included in the Blinded Manuscript.

### *Graphical abstract*

Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view [Example Graphical Abstracts](#) on our information site.

Authors can make use of Elsevier's [Illustration Services](#) to ensure the best presentation of their images and in accordance with all technical requirements.

### *Highlights*

Highlights are a short collection of bullet points that convey the core findings of the article. Highlights are optional and should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point). You can view [example Highlights](#) on our information site.

### **Keywords**

Immediately after the abstract, provide a maximum of 5 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

## Abbreviations

Abbreviations that are unavoidable must be defined twice: (1) at their first mention in the Abstract and (2) at their first mention in the remaining part of the article. Ensure consistency of abbreviations throughout the article.

### Units

Follow internationally accepted rules and conventions: use the international system of units (SI). If other units are mentioned, please give their equivalent in SI.

### Footnotes

Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate the position of footnotes in the text and list the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

## Artwork

### Electronic artwork

#### General points

- Make sure you use uniform lettering and sizing of your original artwork.
- Embed the used fonts if the application provides that option.
- Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Provide captions to illustrations separately.
- Size the illustrations close to the desired dimensions of the published version.
- Submit each illustration as a separate file.

A detailed [guide on electronic artwork](#) is available.

**You are urged to visit this site; some excerpts from the detailed information are given here.**

#### Formats

If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.

Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings, embed all used fonts.

TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.

TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.

TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

#### Please do not:

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
- Supply files that are too low in resolution;
- Submit graphics that are disproportionately large for the content.

### Color artwork

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. **For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article.** Please indicate your preference for color: in print or online only. [Further information on the preparation of electronic artwork.](#)

### Figure captions

Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.



## Tables

Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

## References

### *Citation in text*

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

### *Linking Services Requirements*

Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is encouraged.

A DOI can be used to cite and link to electronic articles where an article is in-press and full citation details are not yet known, but the article is available online. A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic article. An example of a citation using DOI for an article not yet in an issue is: VanDecar JC, Russo RM, James DE, Ambeh WB, Franke M. Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. *J Geophys Res*, 2003. <http://dx.doi.org/10.1029/2001JB000884i>. Please note the format of such citations should be in the same style as all other references in the paper.

### *Web references*

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

### *Data references*

This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

### *References in a special issue*

Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

### *Reference management software*

Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support [Citation Style Language styles](#), such as [Mendeley](#) and [Zotero](#), as well as [EndNote](#). Using the word processor plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide.

### *Reference management software*

This journal has standard templates available in key reference management packages EndNote (<http://endnote.com/downloads/style/vancouver>) and Reference Manager (<http://refman.com/support/rmstyles.asp>). Using plug-ins to wordprocessing packages, authors only need to select the appropriate journal template when preparing their article and the list of references

and citations to these will be formatted according to the journal style which is described below. Other software that can be used for reference management: RefWorks (<http://www.refworks.com>), BibTeX (<http://www.bibtex.org>), ProCite (<http://www.procite.com>).

Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link:

<http://open.mendeley.com/use-citation-style/pharmacological-reports>

When preparing your manuscript, you will then be able to select this style using the Mendeley plugins for Microsoft Word or LibreOffice.

### *Reference style*

The references should be based on the readily available texts published in the latest and major journals mainly written in English. Number the references (numbers in square brackets) in the list in the order in which they appear in the text.

Model of reference to a journal publication:

Last name, initial, full paper title, journal abbreviated title, year, volume (number) first and last page.

*Examples:*

Reference to a journal publication:

[1] Paivio A, Jansen B, Becker LJ. Comparisons through the mind's eye. *Cognition* 1975;37(2):635–47.

Reference to a book:

[2] Letheridge S, Cannon CR, editors. *Bilingual education: teaching English as a second language*. New York: Praeger; 1980.

Reference to a chapter in an edited book:

[3] Strunk Jr W, White EB. *The elements of style*. 3rd ed. New York: MacMillan; 1979 [chapter 4].

Reference to a conference (only abstracts 2-page long may serve as references):

[4] Douglass F, Ball Th. Tracking and viewing changes on the web. In: *Proc. 1996 USENIX technical conference*; 1996.

Reference to a dataset:

[5] Oguro M, Imahiro S, Saito S, Nakashizuka T. Mortality data for Japanese oak wilt disease and surrounding forest compositions, *Mendeley Data*, v1; 2015. <http://dx.doi.org/10.17632/xwj98nb39r.1>.

### **Supplementary material**

Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

### **RESEARCH DATA**

This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the [research data](#) page.

#### *Data linking*

If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the [database linking page](#).

For [supported data repositories](#) a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

#### *Mendeley Data*

This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. During the submission process, after uploading your manuscript, you will have the opportunity to upload your relevant datasets directly to *Mendeley Data*. The datasets will be listed and directly accessible to readers next to your published article online.

For more information, visit the [Mendeley Data for journals page](#).

#### *Data statement*

To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the [Data Statement page](#).

### **ARTICLE ENRICHMENTS**

#### **AudioSlides**

The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar-style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their research in their own words and to help readers understand what the paper is about. [More information and examples are available](#). Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides presentation after acceptance of their paper.

#### **3D models**

You can enrich your online articles by providing 3D models (optional) in PLY, OBJ or U3D format, which will be visualized using the interactive viewer next to the article. Each 3D model will have to be zipped and uploaded to the online submission system via the '3D models' submission category. Please be advised that the recommended model size before zipping is maximum 150 MB. Multiple models can be submitted. Please provide a short informative description for each model by filling in the 'Description' field when uploading a dataset. Note: all datasets will be available for download from the online article on ScienceDirect. If you have concerns about your data being downloadable, please provide a video instead. More information on [OBJ and PLY models](#) or [U3D models](#).

#### **Virtual Microscope**

The journal encourages authors to supplement in-article microscopic images with corresponding high resolution versions for use with the Virtual Microscope viewer. The Virtual Microscope is a web based viewer that enables users to view microscopic images at the highest level of detail and provides features such as zoom and pan. This feature for the first time gives authors the opportunity to share true high resolution microscopic images with their readers. [More information and examples](#). Authors of this journal will receive an invitation e-mail to create microscope images for use with the Virtual Microscope when their manuscript is first reviewed. If you opt to use the feature, please contact [virtualmicroscope@elsevier.com](mailto:virtualmicroscope@elsevier.com) for instructions on how to prepare and upload the required high resolution images.

#### **Interactive Network Viewer**

This journal enables you to enrich your online article by including interactive network diagrams created with the latest version of Cytoscape. Each network should be exported from Cytoscape as a ZIP file containing a pair of network (.cyjs) and visual style (.json) files, which is most easily done using the green "SD" button. The recommended maximum file size of a dataset is 150 MB or less.

Once the article is accepted, your ZIP datasets will appear as supplementary material on ScienceDirect and will be visualized inside the Cytoscape application which is displayed alongside your article. Readers will then be able to interactively explore your networks while reading the article. Please note that you must use the latest available version of Cytoscape. [More information](#).

### **Submission checklist**

The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item.

#### **Ensure that the following items are present:**

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address
- Phone numbers

All necessary files have been uploaded, and contain:

- Abstract (structured for original papers/short communications or unstructured for reviews)
- Keywords
- All figure captions
- All tables (including title, description, footnotes)

Further considerations

- Manuscript has been 'spell-checked' and 'grammar-checked'; authors who are not native English speakers are requested to attach a certificate/statement confirming that professional language editing has been performed
- Paper does not exceed word limits (See Guide for Authors for the word count for each article type)
- Text and tables submitted in editable format (Word, LaTeX)
- Each table, figure, photograph, or illustration included as a separate file
- All symbols converted correctly in the PDF file
- References are in the correct format for this journal
- All references mentioned in the Reference list are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Internet)

Printed version of figures (if applicable) in color or black-and-white

- Indicate clearly whether or not color or black-and-white in print is required.
- For reproduction in black-and-white, please supply black-and-white versions of the figures for printing purposes.

For any further information please visit our customer support site at <http://support.elsevier.com>.

## **AFTER ACCEPTANCE**

### **Online proof correction**

Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

### **Offprints**

The corresponding author will, at no cost, receive a customized [Share Link](#) providing 50 days free access to the final published version of the article on [ScienceDirect](#). The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any

time via Elsevier's [Webshop](#). Corresponding authors who have published their article open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

## **AUTHOR INQUIRIES**

Visit the [Elsevier Support Center](#) to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.

You can also [check the status of your submitted article](#) or find out [when your accepted article will be published](#).

© Copyright 2014 Elsevier | <http://www.elsevier.com>